Unicycive reports Q1 net income $0.5M, cash $19.8M, OLC PDUFA June 28, 2025

Unicycive Therapeutics, Inc.

2025-Q1 EPS reported -$0.05

Net income attributable to common stockholders of $0.5M for Q1 2025, vs net loss of $21.2M in Q1 2024.
Cash and cash equivalents totaled $19.8M as of March 31, 2025.
OLC NDA under FDA review with PDUFA target action date of June 28, 2025; commercial launch preparation ongoing.
R&D expenses fell to $2.2M from $6.8M; G&A rose to $5.8M from $2.4M due to launch prep costs.
Patient survey data presented at NKF and ANNA meetings identified pill burden as primary adherence barrier.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.